Suchergebnisse - (Subject:"O3J8G9O825")

PubPharm (1.792)

61

High-cited favorable studies for COVID-19 treatments ineffective in large trials

enthalten in: Journal of clinical epidemiology | 2022

von Ioannidis, J.

62

The addition of lopinavir-ritonavir to carfilzomib-based triplets can induce meaningful clinical response in carfilzomib-refractory myeloma patients : a single-center experience

enthalten in: Leukemia & lymphoma | 2022

von Bennett, R. | Chan, H. | Henderson, R. | +4

63

Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19 : A randomized clinical trial

enthalten in: Journal of medical virology | 2022

von Hassaniazad, M. | Farshidi, H. | Gharibzadeh, A. | +4

64

Presentation and outcomes of chronic kidney disease patients with COVID-19

enthalten in: Jornal brasileiro de nefrologia | 2022

von Branco, C. | Duarte, I. | Gameiro, J. | +8

65

Population pharmacokinetics of ethambutol in African children : a pooled analysis

enthalten in: The Journal of antimicrobial chemotherapy | 2022

von Tikiso, T. | McIlleron, H. | Abdelwahab, M. | +11

66

HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect

enthalten in: Antiviral research | 2022

von Foo, C. | Abdelnabi, R. | Kaptein, S. | +23

67

Revealing the toxicity of lopinavir- and ritonavir-containing water and wastewater treated by photo-induced processes to Danio rerio and Allivibrio fischeri

enthalten in: The Science of the total environment | 2022

von Czech, B. | Krzyszczak, A. | Boguszewska-Czubara, A. | +3

68

Exposure of human immune cells, to the antiretrovirals efavirenz and lopinavir, leads to lower glucose uptake and altered bioenergetic cell profiles through interactions with SLC2A1

enthalten in: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie | 2022

von Heaton, B. | Jensen, R. | Line, J. | +4

69

Off-Label Use of Hydroxychloroquine in COVID-19 : Analysis of Reports of Suspected Adverse Reactions From the Italian National Network of Pharmacovigilance

enthalten in: Journal of clinical pharmacology | 2022

von Fallani, E. | Cevenini, F. | Lazzerini, P. | +2

70

Safety profile of COVID-19 drugs in a real clinical setting

enthalten in: European journal of clinical pharmacology | 2022

von Chiu, M. | Bhardwaj, M. | Sah, S.